$3.87
7.76%
NYSE, Nov 17, 03:59 pm EST. Closed.
ISIN
US7133171055
Symbol
PEPG

PepGen Stock price

$4.19
+1.59 61.15% 1M
+2.72 185.03% 6M
-2.32 35.64% YTD
-1.16 21.68% 1Y
+0.03 0.72% 3Y
-8.70 67.49% 5Y
-8.70 67.49% 10Y
-8.70 67.49% 20Y
NYSE, Closing price Mon, Nov 16 2026
-0.17 3.90%
ISIN
US7133171055
Symbol
PEPG
Industry

Is PepGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$290.2m
Enterprise Value
$173.0m
Net debt
positive
Cash
$117.2m
Shares outstanding
69.3m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
2.4
Financial Health
Equity Ratio
84.8%
Return on Equity
-60.8%
ROCE
-57.6%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$11.0m | -
SBC as % of FCF
-
SBC Growth 1Y
-11.3%
Share Count Growth 1Y
111.2%
Shareholder Yield
-
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-75.0m
EBIT
$-76.2m
Net Income
$-71.9m
Free Cash Flow | ex SBC
$-69.5m | $-80.4m
Growth
Revenue | estimate
- | -
EBITDA
26.0%
EBIT
25.8%
Net Income
25.8%
Free Cash Flow
23.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.0
FCF per Share
$-1.0
Short interest
6.9%
Employees
56
Rev per Employee
$0.0

PepGen Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a PepGen forecast:

12x Buy
86%
1x Hold
7%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a PepGen forecast:

Buy
86%
Hold
7%
Sell
7%

PepGen Events

Past Events
NOV
10
Special Call - PepGen Inc.
7 days ago
MAR
30
Special Call - PepGen Inc.
8 months ago

Financial data from PepGen

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
5% 5%
-
- Research and Development Expense 53 53
34% 34%
-
-75 -75
26% 26%
-
- Depreciation and Amortization 1.25 1.25
16% 16%
-
EBIT (Operating Income) EBIT -76 -76
26% 26%
-
Net Profit -72 -72
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about PepGen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PepGen Stock News

Neutral
Business Wire
●
6 days ago
BOSTON--(BUSINESS WIRE)--PepGen Announces Pricing of $125.0 Million Public Offering.
Neutral
Business Wire
●
7 days ago
BOSTON--(BUSINESS WIRE)--PepGen Announces Proposed $125.0 Million Public Offering of Common Stock.
Neutral
Business Wire
●
7 days ago
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights.
More PepGen News

Company Profile

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Head office United States
CEO Dr. Mcarthur
Employees 56
Founded 2018
Website pepgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today